An independent advisory committee to the US Food and Drug Administration voted Wednesday to recommend expanded approval of a GLP-1 receptor agonist for slowing kidney disease in patients with type 2 diabetes. The panel met in Silver Spring, Maryland.

The recommendation followed a review of late-stage trial data submitted by the manufacturer showing a statistically significant reduction in the progression of chronic kidney disease. Committee members said the cardiovascular and renal benefits outweighed gastrointestinal side effects documented in the studies.

GLP-1 medicines, originally developed for glycemic control and later for weight loss, have increasingly shown benefits across organ systems. Recent coverage has documented how new therapies and AI monitoring are reshaping diabetes care, with specialists pointing to this drug class as a key driver of that shift.

The FDA is not bound by its advisory panels but typically follows their recommendations. A final decision on labeling is expected within months, and clinicians said expanded approval would widen treatment options for the millions of diabetes patients at risk of progressing to kidney failure and dialysis.

A nephrologist who presented to the committee said: "This vote reflects strong evidence that these therapies protect the kidneys, not just control blood sugar. For patients facing dialysis, that distinction matters enormously."